{
    "clinical_study": {
        "@rank": "159898", 
        "arm_group": [
            {
                "arm_group_label": "Omalizumab (Xolair)", 
                "arm_group_type": "Active Comparator", 
                "description": "Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level."
            }, 
            {
                "arm_group_label": "Placebo (Normal Saline)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate whether addition of Omalizumab enables a\n      reduction in the dose of prednisone in patients with asthma and eosinophilic bronchitis.\n\n      This will be a double-blind placebo-controlled, 3-centre, randomized parallel group trial\n      divided into two sequential study periods.\n\n      Period 1: After establishing the minimum dose of prednisone to maintain asthma control and\n      maintain sputum eosinophils <3%, subjects will be randomized to either placebo or Omalizumab\n      for 16 weeks (either once monthly for 4 months or every 2 weeks for 4 months).\n\n      Period 2: standardised prednisone reduction at intervals of 4-weeks until there is a\n      clinical and eosinophilic exacerbation or bothersome steroid withdrawal effects.  If\n      patients have an exacerbation, they will be treated with prednisone. This patient will\n      continue on Omalizumab or placebo during the entire duration of the study but not continue\n      the phase of steroid reduction."
        }, 
        "brief_title": "Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prednisone Dependent Asthma", 
            "Eosinophilic Bronchitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "Bronchitis", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed asthma within the past 2 years (12% bronchodilator reversibility or PC20\n             methacholine less than 8 mg/ml)\n\n          -  Sputum eosinophils greater than 3% on at least 2 occasions\n\n          -  Asthma Control Questionnaire (ACQ) <1.5 and sputum eos <3% at the time of\n             randomization (ie. optimal steroid dose)\n\n          -  On Inhaled corticosteroids (ICS) and Long acting beta agonist (LABA) (irrespective of\n             dose)\n\n          -  Total serum IgE >120 IU/L\n\n          -  Age between 18 and 75 years\n\n        Exclusion Criteria:\n\n          -  Current smoker or ex-smokers with greater than 20 pack years\n\n          -  Co-morbid diseases which in the investigator's opinion would make the patient\n             unsuitable to participate in the study\n\n          -  Currently on Omalizumab or has previously been treated with Omalizumab\n\n          -  Currently on other biologic therapies\n\n          -  Pregnancy or lactation\n\n          -  Post bronchodilator FEV1 less than 50% predicted"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049294", 
            "org_study_id": "RP 14-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo (Normal Saline)", 
                "intervention_name": "Omalizumab (Xolair)", 
                "intervention_type": "Biological", 
                "other_name": "Anti IgE"
            }, 
            {
                "arm_group_label": "Omalizumab (Xolair)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "0.9% normal saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prednisone", 
                "Omalizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prednisone", 
            "Eosinophils", 
            "Immunoglobin E (IgE)", 
            "Asthma", 
            "Bronchitis", 
            "Inflammation", 
            "Allergy"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "McMaster University"
                }, 
                "investigator": {
                    "last_name": "Parameswaran Nair, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Laval", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "University of Laval"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "University of Montreal"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Double Blind Placebo Controlled Trial of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis", 
        "overall_contact": {
            "email": "mkjarsga@stjoes.ca", 
            "last_name": "Melanie Kjarsgaard", 
            "phone": "905-522-1155", 
            "phone_ext": "33024"
        }, 
        "overall_official": [
            {
                "affiliation": "McMaster University", 
                "last_name": "Parameswaran Nair, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Laval", 
                "last_name": "Louis-Philippe Boulet, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e9 de Montr\u00e9al", 
                "last_name": "Catherine Lemiere, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "McGill University", 
                "last_name": "James Martin, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "proportion of patients with exacerbations in each study group from week 0 to week 32.", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 32"
            }, 
            {
                "measure": "the magnitude of the reduction in the dose of prednisone from week 12 to week 32.", 
                "safety_issue": "No", 
                "time_frame": "week 12 to week 32"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049294"
        }, 
        "responsible_party": {
            "investigator_affiliation": "McMaster University", 
            "investigator_full_name": "Parameswaran Nair", 
            "investigator_title": "Associate Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "change in % sputum eosinophil", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 32"
            }, 
            {
                "measure": "Blood eosinophils", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to week 32"
            }, 
            {
                "measure": "Forced Expired Volume in 1 second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 32"
            }, 
            {
                "measure": "Ratio of Forced Expired Volume in 1 second to Forced Vital Capacity (FEV1/VC)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 32"
            }, 
            {
                "measure": "Provocative concentration causing a 20% drop in FEV1 (PC20)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 32"
            }, 
            {
                "measure": "Asthma Control Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 32"
            }, 
            {
                "measure": "Fraction of exhaled nitric oxide (FeNO)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 32"
            }
        ], 
        "source": "McMaster University", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Parameswaran Nair", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}